Zydus Lifesciences Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Zydus Lifesciences reported consolidated revenue of Rs. 271.5 billion for FY2025-26, growth of 17% over the previous year, with an EBITDA margin of 31.2%. Management described growth across India formulations, international markets, and Consumer Wellness, along with new entries into MedTech and biosimilars, and disclosed a post-year-end share buyback of up to Rs. 1,100 crore at Rs. 1,260 per share. Management also said the company expects high-teen revenue growth in FY27, supported by its Indian and international businesses, new product launches, and integration of recent acquisitions.
Zydus Lifesciences reported consolidated revenue of ₹271.5 billion for FY26, up 17% year-on-year, with EBITDA margin at 31.2% and net profit adjusted for exceptional items at ₹54.6 billion, up 15%. Q4 FY26 revenue was ₹75.9 billion, up 16% year-on-year, with EBITDA margin of 33.7% and adjusted net profit of ₹15.9 billion. Management discussed growth across US formulations, India branded formulations, international markets, consumer wellness and medical devices, along with the proposed acquisition of Assertio Holdings and other pipeline updates.